L'Oréal Shares Drop 1.06% at Close
L'Oréal's stock ended the trading session on Tuesday, December 23, at 362.55 euros, down 1.06% from the previous day's close of 366.45 euros. Trading remained particularly limited with only 0.04% of the capital changing hands, indicating low activity typical of this end-of-year period. This correction is part of a short-term downward trend, with the stock showing a weekly decline of 2.85%. On a quarterly horizon, the French cosmetics giant still manages to maintain a slight increase of 0.15%, while the annual performance stands at 7.6%, demonstrating the group's relative resilience in a mixed sector environment. The price is now below its 50-day moving average at 368.71 euros, and also below its 200-day moving average at 372.37 euros, signaling a consolidation phase after recent movements.
On December 12, L'Oréal was recognized with a triple AAA rating by the environmental organization CDP for the tenth consecutive year, becoming the first and only company to achieve this distinction for its performance in climate, forests, and water security. These announcements extend a series of major strategic operations begun in October with the acquisition of Kering Beauté for 4 billion euros, the largest in the group's history, and the strengthening in December of its stake in Galderma, the Swiss dermatology specialist, to 20% of the capital.
From a technical analysis perspective, the stock has an RSI of 43, indicating a neutral territory without a marked oversold signal, which gives investors some leeway. The MACD configuration remains slightly negative with a MACD line at 2.09 points below the signal line at 2.54 points, producing a negative histogram of 0.45 point suggesting a very short-term bearish momentum. The price is between a support threshold identified at 350.65 euros and a resistance at 377.95 euros, offering a range of variation of about 7.5% in both directions. The moderate monthly volatility of 4.44% and a nearly zero beta at -0.04 confirm a relatively uncorrelated evolution from the movements of the CAC 40. Investors will await the 2025 annual results scheduled for February 12, 2026, to assess the group's outlook after a year marked by an ambitious acquisition strategy aimed at consolidating its position in high-growth segments of dermatology, medical aesthetics, and Asian luxury. Deutsche Bank's recommendation remains a sell with a target price of 340 euros, representing a potential downside of 6.2% from the current price.
